[Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Isolated limb perfusion (ILP) with tumor necrosis factor (TNF) and melphalan was carried out in 21 patients with regionally metastatic malignant melanoma of the limbs. The observed response rate was 65% complete and 15% partial remission. These results warrant further investigation of ILP with TNF and melphalan vs ILP with melphalan alone in a prospective randomised multicenter trial.
Kettelhack
C
C
Humboldt-Universität, Virchow-Klinikum, Robert-Rössle-Klinik, Berlin.
Hohenberger
P
P
Schlag
P M
PM
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005121:Extremities; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage*; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
D018906:Antineoplastic Agents, Alkylating; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan
Die isolierte hypertherme Extremitätenperfusion beim Malignen Melanom mit Melphalan und Tumornekrosefaktor.